Your browser does not support JavaScript!
COVID-19 : Découvrez les Plans de Continuité d’Activité des entreprises de la biotechnologies
Logo de Labiotech.eu

Labiotech.eu Source d'actualité

Une actualité de Labiotech.eu a été ajouté(e)
Aujourd'hui à 12:12
Evonik and Beiersdorf Team Up to Turn CO? into Skin Care Products
The German companies Evonik and Beiersdorf will work together on a joint research project to investigate how bacteria can be used to turn carbon dioxide (CO?) and water into raw materials for skincare...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Aujourd'hui à 08:34
Could Cell Therapy Target the Symptoms of Severe Covid-19?
The excessive inflammatory response seen in the most serious cases of Covid-19, along with shortages of ventilators, has caused a healthcare crisis in many countries around the world. Could cell...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Hier à 08:34
Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease
An initially promising drug has failed to show benefits in a phase II trial for the rare kidney disease focal segmental glomerulosclerosis (FSGS), prompting the US biotech ChemoCentryx and its Swiss...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 4 jours
Antibacterial Eliminates Recurrence of C. Difficile Infections in Phase II
MGB Biopharma has reported positive results from a phase II trial showing that its antibacterial treatment for Clostridium difficile infections cured 100% of the patients, who showed no recurrence...
www.labiotech.eu
Une actualité de Labiotech.eu a été ajouté(e)
Il y a 4 jours
Phase II Success for Once-a-Day Eye Drops after Cataract Surgery
A nanoparticle steroid therapy developed by Swiss biotech Oculis has reduced eye pain and inflammation in a phase II trial in cataract surgery patients. This is the second positive phase II this year...
www.labiotech.eu
Charger plus d'actualités

Informations juridiques
SIREN / SIRET - DE Labiotech

Adresse
Berlin Berlin DE Allemagne